[1] |
JANOIR C.Virulence factors of Clostridium difficile and their role during infection[J]. Anaerobe,2016,37:13-24.
|
[2] |
DAVIES A H,ROBERTS A K,SHONE C C,et al.Super toxins from a super bug:structure and function of Clostridium difficile toxins[J]. Biochem J,2011,436(3):517-526.
|
[3] |
POPOFF M R,RUBIN E J,GILL D M,et al.Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain[J]. Infect Immun,1988,56(9):2299-2306.
|
[4] |
SHEN A.Clostridium difficile toxins:mediators of inflammation[J]. J Innate Immun,2012,4(2):149-158.
|
[5] |
SMITS W K,LYRAS D,LACY D B,et al.Clostridium difficile infection[J]. Nat Rev Dis Primers,2016,2:16020.
|
[6] |
LAI H,HUANG C,CAI J,et al.Simultaneous detection and characterization of toxigenic Clostridium difficile directly from clinical stool specimens[J]. Front Med,2018,12(2):196-205.
|
[7] |
CHENG V C,YAM W C,CHAN J F,et al.Clostridium difficile ribotype 027 arrives in Hong Kong[J]. Int J Antimicrob Agents,2009,34(5):492-493.
|
[8] |
BALDONI D,GUTIERREZ M,TIMMER W,et al.Cadazolid,a novel antibiotic with potent activity against Clostridium difficile:safety,tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses[J]. J Antimicrob Chemother,2014,69(3):706-714.
|
[9] |
FIMLAID K A,BOND J P,SCHUTZ K C,et al.Global analysis of the sporulation pathway of Clostridium difficile[J]. PLoS Genet,2013,9(8):e1003660.
|
[10] |
LEUZZI R,ADAMO R,SCARSELLI M.Vaccines against Clostridium difficile[J]. Hum Vaccin Immunother,2014,10(6):1466-1477.
|
[11] |
CHAI J,LEE C H.Management of primary and recurrent Clostridium difficile infection:an update[J]. Antibiotics (Basel),2018,7(3):54.
|
[12] |
刘思娣,吴安华. 艰难梭菌毒力与芽孢研究进展[J]. 中国感染控制杂志,2016,15(6):436-440.
|
[13] |
STEELE S R,MCCORMICK J,MELTON G B,et al.Practice parameters for the management of Clostridium difficile infection[J]. Dis Colon Rectum,2015,58(1):10-24.
|
[14] |
张文竹,闫中强,李文革,等. 老年人群分离艰难梭菌分子型别特征研究[J]. 中华医院感染学杂志,2018,28(8):1121-1125.
|